ABUS · Arbutus Biopharma Corp
$4.41
+0.00 (+0.00%)
At close · Jul 28
Market Cap
$871.14M
Shares
197.54M
Arbutus Biopharma Corp Earnings Call Transcripts
Every quarterly earnings call for Arbutus Biopharma Corp (ABUS) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲47.5%
$2.39M
−$17.04M
'20 Q4
21-01-25
▲41.7%
$2.11M
−$16.38M
'21 Q1
21-05-05
▲53.8%
$2.33M
−$19.39M
'21 Q2
21-08-05
▲119.3%
$3.34M
−$19.16M
'21 Q3
21-11-04
▲34.4%
$3.21M
−$21.32M
'21 Q4
22-01-24
▲495.4%
$12.58M
−$15.77M
'22 Q1
22-05-05
▲511.5%
$14.24M
−$14.19M
'22 Q2
22-08-04
▲78.2%
$5.95M
−$17.57M
'22 Q3
22-11-09
▲94.8%
$6.25M
−$21.93M
'22 Q4
23-01-05
▼46.8%
$6.69M
−$16.34M
'23 Q1
23-05-04
▼67.3%
$4.65M
−$17.09M
'23 Q2
23-08-03
▼21.7%
$4.66M
−$20.10M
'23 Q3
23-11-07
▼65.7%
$2.15M
−$19.31M
'23 Q4
24-02-29
▼77.1%
$1.53M
−$17.88M
'24 Q1
24-05-02
▼62.9%
$1.73M
−$19.80M
'24 Q2
24-08-01
LATEST
▼71.3%
$1.34M
−$19.72M
'24 Q3
24-11-06
Earnings call
FY24 · Q3
2024-11-06
Arbutus Biopharma Corp Q3 FY2024 Earnings Call
Positive tone
Imdusiran (RNAi therapeutic) in HBV
AB-101 oral PD-L1 inhibitor
HBV disease burden and unmet need
Revenue
$1.34M
▼ 71.3% YoY Diluted EPS
$-0.10
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Arbutus Biopharma Corp Q2 FY2024 Earnings Call
Positive tone
imdusiran Phase 2a combination data
AB-101 PD-L1 checkpoint inhibitor
Phase 2b clinical development planning
Revenue
$1.73M
▼ 62.9% YoY Diluted EPS
$-0.11
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-02
Arbutus Biopharma Corp Q1 FY2024 Earnings Call
Positive tone
Imdusiran combination trials (Phase 2a)
AB-101 Phase 1 clinical development
HBV functional cure strategy
Revenue
$1.53M
▼ 77.1% YoY Diluted EPS
$-0.10
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-29
Arbutus Biopharma Corp Q4 FY2023 Earnings Call
Positive tone
HBV Pipeline / Imdusiran
Strategic Combinations / Partnerships
AB-101 PD-L1 Inhibitor
Revenue
$2.15M*
▼ 65.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Arbutus Biopharma Corp Q3 FY2023 Earnings Call
Revenue
$4.66M
▼ 21.7% YoY Diluted EPS
$-0.12
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Arbutus Biopharma Corp Q2 FY2023 Earnings Call
Revenue
$4.65M
▼ 67.3% YoY Diluted EPS
$-0.10
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Arbutus Biopharma Corp Q1 FY2023 Earnings Call
Revenue
$6.69M
▼ 46.8% YoY Diluted EPS
$-0.10
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-01-05
Arbutus Biopharma Corp Q4 FY2022 Earnings Call
Revenue
$6.25M*
▲ 94.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-09
Arbutus Biopharma Corp Q3 FY2022 Earnings Call
Revenue
$5.95M
▲ 78.2% YoY Diluted EPS
$-0.12
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Arbutus Biopharma Corp Q2 FY2022 Earnings Call
Revenue
$14.24M
▲ 511.5% YoY Diluted EPS
$-0.10
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Arbutus Biopharma Corp Q1 FY2022 Earnings Call
Revenue
$12.58M
▲ 495.4% YoY Diluted EPS
$-0.11
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-01-24
Arbutus Biopharma Corp Q4 FY2021 Earnings Call
Revenue
$3.21M*
▲ 34.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-04
Arbutus Biopharma Corp Q3 FY2021 Earnings Call
Revenue
$3.34M
▲ 119.3% YoY Diluted EPS
$-0.24
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Arbutus Biopharma Corp Q2 FY2021 Earnings Call
Revenue
$2.33M
▲ 53.8% YoY Diluted EPS
$-0.23
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-05
Arbutus Biopharma Corp Q1 FY2021 Earnings Call
Revenue
$2.11M
▲ 41.7% YoY Diluted EPS
$-0.21
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-01-25
Arbutus Biopharma Corp Q4 FY2020 Earnings Call
Revenue
$2.39M*
▲ 47.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Arbutus Biopharma Corp Q3 FY2020 Earnings Call
Revenue
$1.52M
▼ 50.2% YoY Diluted EPS
$-0.27
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-07
Arbutus Biopharma Corp Q2 FY2020 Earnings Call
Revenue
$1.51M
▲ 131.9% YoY Diluted EPS
$-0.25
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-11
Arbutus Biopharma Corp Q1 FY2020 Earnings Call
Revenue
$1.49M
▲ 119.6% YoY Diluted EPS
$-0.25
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-03-05
Arbutus Biopharma Corp Q4 FY2019 Earnings Call
Revenue
$1.62M
▼ 3.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–20 of 20 earnings calls